康龙化成（北京）新药技术股份有限公司 关于选举产生第三届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300759 证券简称：康龙化成 公告编号：2025-068 本次职工代表董事选举产生后，公司第三届董事会中兼任高级管理人员职务 的董事以及由职工代表担任的董事，总计不超过公司董事总数的二分之一，符合 相关法律、法规及《公司章程》的有关规定。上述职工代表董事符合《公司法》 及《公司章程》有关董事任职的资格和条件，将按照法律、法规、规章、规范性 文件及《公司章程》的要求认真履行董事职责。 特此公告。 康龙化成（北京）新药技术股份有限公司董事会 2025 年 12 月 18 日 附件： 李承宗（Gilbert Shing Chung Li）先生，47 岁，现任公司首席财务官兼董 事会秘书。2008 年 1 月加入公司担任财务总监，于 2015 年 1 月获委任为公司首 席财务官，2016 年 10 月获委任为公司董事会秘书，主要负责公司整体财务职能， 特别是公司的融资及并购活动。李承宗先生加入公司前曾担任多项会计及财务范 畴的 ...

康龙化成（北京）新药技术股份有限公司 章程 （经公司于 2025 年 12 月 18 日召开的 2025 年第一次临时股东大会审议通过） 中国 北京 | 第一章 | 总则 | 1 | | --- | --- | --- | | 第二章 | 经营宗旨和经营范围 | 3 | | 第三章 | 股份 | 3 | | 第一节 | 股份发行 | 3 | | 第二节 | 股份增减和回购 | 6 | | 第三节 | 股份转让 | 8 | | 第四章 | 股东和股东会 | 10 | | 第一节 | 股东 | 10 | | 第二节 | 控股股东和实际控制人 14 | | | 第三节 | 股东会的一般规定 15 | | | 第四节 | 股东会的召集 | 21 | | 第五节 | 股东会的提案与通知 23 | | | 第六节 | 股东会的召开 | 26 | | 第七节 | 股东会的表决和决议 31 | | | 第八节 | 类别股东表决的特别程序 37 | | | 第五章 | 董事会 | 40 | | 第一节 | 董事 | 40 | | 第二节 | 董事会 | 44 | | 第三节 | 独立非执行董事 51 | | | 第四节 | 董 ...

Group 1 - A total of 78 stocks in the A-share market experienced block trading today, with a total transaction value of 3.755 billion yuan [1] - The top three stocks by transaction value were Minsheng Bank (2.149 billion yuan), WuXi AppTec (430 million yuan), and Luxin Technology (119 million yuan) [1] - Among the stocks, 8 were traded at par, 3 at a premium, and 67 at a discount; the highest premium rates were for AVIC Optoelectronics (8.04%), Zhongke Shuguang (7.92%), and Haowei Group (2.07%) [1] Group 2 - The top buying amounts from institutional special seats were led by WuXi AppTec (251 million yuan) and Minsheng Bank (108 million yuan) [2] - The top selling amounts from institutional special seats included Jintian Titanium Industry (18.74 million yuan) and Huilong New Materials (9.97 million yuan) [2]

Investment Rating - The report maintains an "Overweight" rating for the CXO industry, indicating a positive outlook for investment opportunities in this sector [7]. Core Insights - The CXO industry is entering a new high prosperity cycle driven by external factors such as overseas interest rate cuts, domestic recovery, and industrial upgrades. The worst period for the industry is considered to be over, with a significant improvement in sentiment and operational conditions [1][2][17]. - The report emphasizes the competitive advantages of Chinese CXO companies, including efficiency, cost, quality, and rapid expansion capabilities, which are expected to maintain their global standing in the short to medium term [1][3][22]. - The emergence of new molecular drugs, such as peptides and oligonucleotides, is driving growth in the CRDMO sector, with Chinese suppliers positioned to lead globally due to their production capabilities and cost advantages [3][22][28]. Summary by Sections New Cycle - The CXO industry has transitioned from a prolonged adjustment period (2H21-1H24) to a new upward cycle, supported by recovering overseas financing and a favorable domestic IPO environment. The demand for CXO services is expected to increase significantly starting in 2026 [2][17]. New Molecules - New molecular CRDMO services are characterized by higher demand and technical barriers. Chinese companies are leading in areas like TIDES and ADC, achieving higher growth rates and maintaining robust profit margins [3][22][28]. New Landscape - The domestic CXO market is undergoing a restructuring, with market share increasingly concentrated among leading firms. The report highlights that smaller companies may struggle to survive due to heightened quality and sustainability demands from pharmaceutical clients [4][22][28]. Key Recommendations - The report recommends investing in leading companies with strong positions in the new molecular space, such as WuXi AppTec, WuXi Biologics, and others, which are expected to benefit from the ongoing industry upgrades and demand recovery [1][9][22].

Core Insights - The pharmaceutical industry is experiencing a surge in innovative products, with clear domestic demand and significant potential for international expansion [4][14][25] - Investment opportunities are concentrated in innovative drugs and their supply chains, with a notable performance from CRO/CMO and chemical pharmaceuticals [9][15][17] - The report emphasizes the importance of innovation as the primary solution to industry challenges, driven by stable demand and supportive policies [26][32][41] Industry Overview - The pharmaceutical sector has faced revenue declines, with a 0.9% year-on-year decrease in revenue for the first three quarters of 2025, and net profit down by 2.2% [15][16] - The innovative drug sector has outperformed, with CRO/CMO and chemical pharmaceuticals showing net profit growth of 31.0% and 16.6% respectively [17][18] - The overall market is characterized by low fund holdings and historical valuation bottoms, indicating high investment value [20][25] Demand and Payment Dynamics - The demand for healthcare services is steadily increasing, with a projected 5% growth in total medical visits and hospital admissions in 2024 [26][28] - The aging population is expected to drive long-term demand, with 220 million people aged 65 and above by 2050 [28][30] - The medical insurance fund's income growth has outpaced expenditure growth, leading to a significant increase in fund reserves [32][36] Financing and Market Trends - The IPO market for healthcare has rebounded, with 28 IPOs in the first three quarters of 2025, a 100% increase from the previous year [42][43] - License-out transactions have surged, with transaction numbers increasing by 41% and total amounts reaching $92 billion, indicating a robust market for innovative drug licensing [48][50] - The number of IND applications and new clinical trials for innovative drugs has been steadily increasing, with a notable rise in NDA approvals [53][57] Technological Advancements - The report highlights the emergence of new technologies such as ADC and small nucleic acids, with domestic companies leading in these areas [60] - The focus on dual antibodies and GLP-1 drugs is expected to drive significant growth, with multiple development directions emerging [9][60] - The report notes that domestic companies are increasingly recognized for their innovative capabilities, particularly in the ADC space [60]

Group 1 - The core point of the news is that Kanglong Chemical conducted three block trades on December 12, totaling 1.484 million shares and a transaction amount of 44.0624 million yuan, with one trade executed at a discount rate of 0.90% [1][2] - Institutional proprietary seats participated in all three trades, with a total transaction amount of 44.0624 million yuan and a net purchase of 35.568 million yuan [1][2] - Over the past three months, Kanglong Chemical has recorded four block trades with a cumulative transaction amount of 67.6949 million yuan [1] Group 2 - The closing price of Kanglong Chemical on December 12 was 29.91 yuan, reflecting an increase of 2.96%, with a daily turnover rate of 2.45% and a total transaction amount of 1.035 billion yuan [1] - The net inflow of main funds for the day was 36.8064 million yuan, and the stock has increased by 2.40% over the past five days, with a total net inflow of 47.4292 million yuan [1] - The latest financing balance for the stock is 1.098 billion yuan, with an increase of 17.8699 million yuan over the past five days, representing a growth rate of 1.65% [2]

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 （股份代號：3759） Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） 海外監管公告 本公告乃康龍化成（北京）新藥技術股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條作出。 茲載列本公司於深圳證券交易所網站刊登公告如下，僅供參閱。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 中華人民共和國，北京 2025年12月11日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事李家慶先生及萬璇女士；獨立非執行董事李麗華女士、曾坤鴻先生及余堅 先生。 证券代码：300759 证券简称：康龙化成 公告编号：2025-066 康龙化成（北京）新药技术股份有限公司 ...

Group 1 - The core point of the article highlights a significant block trade involving Kanglong Chemical on December 10, with a transaction volume of 810,000 shares and a transaction amount of 23.63 million yuan, executed at a price of 29.14 yuan, which represents a discount of 0.78% compared to the closing price of the day [1] Group 2 - On December 10, Kanglong Chemical's closing price was 29.37 yuan, reflecting an increase of 0.93%, with a daily turnover rate of 1.06% and a total transaction amount of 439 million yuan, alongside a net inflow of main funds amounting to 6.76 million yuan [1] - Over the past five days, the stock has seen a cumulative increase of 1.84%, while the total net outflow of funds during this period reached 79.28 million yuan [1] - The latest margin financing balance for Kanglong Chemical stands at 1.104 billion yuan, with an increase of 20.32 million yuan over the past five days, representing a growth rate of 1.88% [1] - Kanglong Chemical (Beijing) New Drug Technology Co., Ltd. was established on July 1, 2004, with a registered capital of 1.778 billion yuan [1]

Investment Rating - The report maintains a "Buy" rating for certain stocks in the CXO sector, indicating a positive outlook for the industry [58]. Core Insights - The global market is showing signs of recovery, with domestic financing on the rise, particularly in the healthcare sector. In Q3 2025, global financing reached $20.6 billion, marking a 39% increase and the highest in nearly four years. Domestic financing also surged to 18.2 billion yuan, up 97% [2][21]. - The IPO landscape is experiencing a divergence, with overseas markets facing challenges while domestic IPOs are rebounding. The domestic biotech IPOs have seen significant growth, with a 665% year-on-year increase in fundraising [30][34]. - The research and development sector is under pressure globally, but domestic R&D is showing rapid improvement, with new clinical trials reaching historical highs. In the first eleven months of 2025, the number of new clinical trials in China increased by 20% [41][52]. Summary by Sections Financing Sector - Global financing in the healthcare sector is recovering, with Q3 2025 showing a significant rebound. The total financing for the first ten months of 2025 has already surpassed the entire year of 2024 [14][21]. - Domestic financing trends mirror global patterns, with a notable increase in Q3 2025, indicating a clear upward trajectory [21][22]. IPO Trends - The overseas IPO market is stabilizing after a downturn, while domestic IPOs are experiencing a resurgence, particularly in the biotech sector, driven by a favorable secondary market [30][34]. - The first eleven months of 2025 saw a dramatic increase in fundraising from domestic biotech IPOs, highlighting a strong recovery [34][36]. R&D Developments - Globally, the number of new clinical trials is declining, but the domestic market is witnessing a significant turnaround, with new drug IND applications showing stability and growth [41][47]. - The number of new clinical trials in China has reached a historical high, with a notable increase in Phase II trials, indicating a robust pipeline for future drug development [52][53].

致：香港交易及結算所有限公司 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年12月2日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 300759 | 說明 | | A 股 (深圳證券交易所) | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,476,658,400 | RMB | | 1 RMB | | 1,476,658,400 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 1,476,658,400 | RMB | | 1 RMB | | 1,476,65 ...